Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.1
The study analyzed 700,612 adults in a US cancer data registry. Patients were between the ages of 20 and 84 years and had their first primary solid cancer diagnosed between 2000 and 2013, and they survived 1 year or longer. One year after the primary diagnosis, patients were followed until second cancer diagnosis, death, age 85, loss of follow-up, or the end of the study.
“Although the absolute risk of developing tMDS/AML is low, its treatment is often resource intensive and associated with substantial morbidity; overall survival is poor, highlighting its clinical significance,” the authors explained.
Among the 700,612 adults analyzed, there were 1619 cases of tMDS/AML and the researchers found elevated risks of tMDS/AML for all 22 cancers. The risks were highest after chemotherapy for bone, soft tissue, and testis cancers. Therapy-related MDS/AML risks were not elevated in patients treated with chemotherapy for colon cancer.
According to the authors, this study is the first to provide clear evidence that chemotherapy for oral cavity or pharynx, esophagus, stomach, rectum, larynx, bone, cervix, uterine corpus, and vagina or vulva cancers is associated with an risk of tMDS/AML.
In an accompany editorial,2 Shyam A. Patel, MD, PhD, of the Stanford Cancer Institute at Stanford University School of Medicine, highlighted the study’s finding that treatment with chemotherapy at a young age actually posed the highest relative risk.
He added that the study raises the question of how to perform a risk assessment of chemotherapy used to treat solid tumors.
“Future efforts should be focused specifically on patients who are at highest risk of tMDS/AML. It is critical that risk assessment models for tMDS/AML consider the clonal evolution of subclinical mutations into overt, clinically apparent disease,” he concluded.
1. Morton LM, Dores GM, Schonfeld SJ, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. [published online December 20, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.5625.
2. Patel SA. Myelodysplastic syndrome and acute myeloid leukemiar risk associated with solid tumor chemotherapy. [published online December 20, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.5617.
References
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More